Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Other financing activities (2018 - 2025)

Iovance Biotherapeutics (IOVA) has disclosed Other financing activities for 5 consecutive years, with -$447000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Other financing activities rose 49.2% to -$447000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was -$7.1 million, a 45.1% increase, with the full-year FY2025 number at -$7.1 million, up 45.1% from a year prior.
  • Other financing activities was -$447000.0 for Q4 2025 at Iovance Biotherapeutics, up from -$464000.0 in the prior quarter.
  • In the past five years, Other financing activities ranged from a high of -$186000.0 in Q4 2023 to a low of -$6.3 million in Q3 2024.
  • A 3-year average of -$1.9 million and a median of -$692000.0 in 2024 define the central range for Other financing activities.
  • Peak YoY movement for Other financing activities: tumbled 1556.2% in 2024, then surged 92.61% in 2025.
  • Iovance Biotherapeutics' Other financing activities stood at -$186000.0 in 2023, then tumbled by 373.12% to -$880000.0 in 2024, then surged by 49.2% to -$447000.0 in 2025.
  • Per Business Quant, the three most recent readings for IOVA's Other financing activities are -$447000.0 (Q4 2025), -$464000.0 (Q3 2025), and -$504000.0 (Q2 2025).